Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D3MGD9
|
|||
| Drug Name |
ITIL-306
|
|||
| Drug Type |
Cell therapy
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1 | [1] | |
| Company |
Instill Bio Dallas, TX
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05397093) A Phase 1a/1b, Open-Label, Multicenter Study Evaluating the Safety and Feasibility of ITIL-306 in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.